Celldex (#$CLDX): Both Phase 3 CSU Trials Meet Primary Endpoints, BLA Planned in 2027
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/celldex-ther...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/celldex-ther...
September 23, 2026 at 3:50 PM
Celldex (#$CLDX): Both Phase 3 CSU Trials Meet Primary Endpoints, BLA Planned in 2027
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/celldex-ther...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/celldex-ther...
HC Wainwright Increases Celldex Therapeutics (NASDAQ:CLDX) Price Target to $64.00
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) had its target price boosted by investment analysts at HC Wainwright from $42.00 to $64.00 in a research note issued on Tuesday, MarketBeat…
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) had its target price boosted by investment analysts at HC Wainwright from $42.00 to $64.00 in a research note issued on Tuesday, MarketBeat…
HC Wainwright Increases Celldex Therapeutics (NASDAQ:CLDX) Price Target to $64.00
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) had its target price boosted by investment analysts at HC Wainwright from $42.00 to $64.00 in a research note issued on Tuesday, MarketBeat…
news-area.com
September 24, 2026 at 5:58 PM
HC Wainwright Increases Celldex Therapeutics (NASDAQ:CLDX) Price Target to $64.00
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) had its target price boosted by investment analysts at HC Wainwright from $42.00 to $64.00 in a research note issued on Tuesday, MarketBeat…
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) had its target price boosted by investment analysts at HC Wainwright from $42.00 to $64.00 in a research note issued on Tuesday, MarketBeat…
🚨 JUST IN: $CLDX
Celldex barzolvolimab hits all primary and key secondary endpoints in two Phase 3 CSU trials
#SEC #stocks #investing #CLDX
🔗 secwatch.observer
Celldex barzolvolimab hits all primary and key secondary endpoints in two Phase 3 CSU trials
#SEC #stocks #investing #CLDX
🔗 secwatch.observer
September 22, 2026 at 11:10 AM
🚨 JUST IN: $CLDX
Celldex barzolvolimab hits all primary and key secondary endpoints in two Phase 3 CSU trials
#SEC #stocks #investing #CLDX
🔗 secwatch.observer
Celldex barzolvolimab hits all primary and key secondary endpoints in two Phase 3 CSU trials
#SEC #stocks #investing #CLDX
🔗 secwatch.observer
#$CLDX Barzolvolimab met every Phase 3 CSU goal, with 42–54% complete responses. Shares still fell on high expectations, thin safety detail, and oral/injectable rivals. notreload.xyz/xy/celldex-c...
Celldex CSU Readout Succeeds. Investors Wanted More
Barzolvolimab met every Phase 3 CSU goal, with 42–54% complete responses. Shares still fell on high expectations, thin safety detail, and oral/injectable rivals.
notreload.xyz
September 22, 2026 at 12:23 PM
#$CLDX Barzolvolimab met every Phase 3 CSU goal, with 42–54% complete responses. Shares still fell on high expectations, thin safety detail, and oral/injectable rivals. notreload.xyz/xy/celldex-c...
Celldex Therapeutics $CLDX: Morgan Stanley raised its price target from $50.00 to $57.00 and maintained its Overweight rating.
https://fundspec.ai/s/CLDX/analysts
Get a push the moment an analyst moves a price target.
https://fundspec.ai/s/CLDX/analysts
Get a push the moment an analyst moves a price target.
September 23, 2026 at 11:45 AM
Celldex Therapeutics $CLDX: Morgan Stanley raised its price target from $50.00 to $57.00 and maintained its Overweight rating.
https://fundspec.ai/s/CLDX/analysts
Get a push the moment an analyst moves a price target.
https://fundspec.ai/s/CLDX/analysts
Get a push the moment an analyst moves a price target.
1/6 🧬 $CLDX Celldex Therapeutics has raised full-year guidance, InsiderWatch flagged the strong bullish signal in its 8-K filing on September 22. The biotech company's Item 8.01 disclosure reflects management's confidence in near-term execution and financial trajectory.
Read the full story
CLDX Raises Full-Year Guidance on Stronger-Than-Expected Momentum
InsiderWatch | insider.wizybit.com
insider.wizybit.com
September 24, 2026 at 1:25 PM
1/6 🧬 $CLDX Celldex Therapeutics has raised full-year guidance, InsiderWatch flagged the strong bullish signal in its 8-K filing on September 22. The biotech company's Item 8.01 disclosure reflects management's confidence in near-term execution and financial trajectory.
#Healthcare Celldex Therapeutics reported positive top-line results Tuesday from its two pivotal Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab in adults with chronic spontaneous urticaria, a condition causing persistent hives, yet shares of CLDX fell roughly 28.6% ... Continue reading
September 22, 2026 at 9:30 PM
#Healthcare Celldex Therapeutics reported positive top-line results Tuesday from its two pivotal Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab in adults with chronic spontaneous urticaria, a condition causing persistent hives, yet shares of CLDX fell roughly 28.6% ... Continue reading
#Healthcare Celldex Therapeutics reported positive top-line results Tuesday from its two pivotal Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab in adults with chronic spontaneous urticaria, a condition causing persistent hives, yet shares of CLDX fell roughly 28.6% ... Continue reading
September 22, 2026 at 9:35 PM
#Healthcare Celldex Therapeutics reported positive top-line results Tuesday from its two pivotal Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab in adults with chronic spontaneous urticaria, a condition causing persistent hives, yet shares of CLDX fell roughly 28.6% ... Continue reading
Besides learning #BASH, I explored #R packages such as #tidyverse, #ggplot2, #DESeq2, #GEOquery, #org.Hs.eg.db, #clusterProfiler, #EnhancedVolcano, #celldex, #pheatmap, and #pathview, which open doors to further exploration of #RNASeq data. #Bioinformatics #RProgramming #Linux
January 14, 2025 at 5:50 PM
Besides learning #BASH, I explored #R packages such as #tidyverse, #ggplot2, #DESeq2, #GEOquery, #org.Hs.eg.db, #clusterProfiler, #EnhancedVolcano, #celldex, #pheatmap, and #pathview, which open doors to further exploration of #RNASeq data. #Bioinformatics #RProgramming #Linux
🚨 $CLDX
On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of Barzolvolimab in chronic spontaneous urticaria (CSU). A copy of this press release is attached hereto as Exhibit 99.1 hereto and is incorp...
On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of Barzolvolimab in chronic spontaneous urticaria (CSU). A copy of this press release is attached hereto as Exhibit 99.1 hereto and is incorp...
SEC Filing: CLDX
Click to view the official SEC document.
www.sec.gov
September 22, 2026 at 11:10 AM
🚨 $CLDX
On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of Barzolvolimab in chronic spontaneous urticaria (CSU). A copy of this press release is attached hereto as Exhibit 99.1 hereto and is incorp...
On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of Barzolvolimab in chronic spontaneous urticaria (CSU). A copy of this press release is attached hereto as Exhibit 99.1 hereto and is incorp...
CuraGen (founded in 1991):
Focused on leveraging genomics for drug discovery and development.
Sold its key assets to Celldex Therapeutics in 2009.
Focused on leveraging genomics for drug discovery and development.
Sold its key assets to Celldex Therapeutics in 2009.
December 20, 2024 at 2:55 PM
CuraGen (founded in 1991):
Focused on leveraging genomics for drug discovery and development.
Sold its key assets to Celldex Therapeutics in 2009.
Focused on leveraging genomics for drug discovery and development.
Sold its key assets to Celldex Therapeutics in 2009.
Celldex Therapeutics ($CLDX) reported EPS of -1.18 missing estimate of -1.13 for Q1 2026. Revenue 15000.0 Vs 952800.0 expected.
https://fundspec.vembar.io/CLDX
Get the most comprehensive financial analysis on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.vembar.io/CLDX
Get the most comprehensive financial analysis on the FundSpec App available on the AppStore or PlayStore!
May 7, 2026 at 10:00 PM
Celldex Therapeutics ($CLDX) reported EPS of -1.18 missing estimate of -1.13 for Q1 2026. Revenue 15000.0 Vs 952800.0 expected.
https://fundspec.vembar.io/CLDX
Get the most comprehensive financial analysis on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.vembar.io/CLDX
Get the most comprehensive financial analysis on the FundSpec App available on the AppStore or PlayStore!
Authors published a paper in Biorxiv, they used celldex in the study. Including #RRIDs will make this less ambiguous.
SciScore made a table with this resource, see “Automated Services” module (download as csv, xml or #jats) #RRID #OpenScience
SciScore made a table with this resource, see “Automated Services” module (download as csv, xml or #jats) #RRID #OpenScience
www.biorxiv.org
June 19, 2026 at 12:00 PM
Authors published a paper in Biorxiv, they used celldex in the study. Including #RRIDs will make this less ambiguous.
SciScore made a table with this resource, see “Automated Services” module (download as csv, xml or #jats) #RRID #OpenScience
SciScore made a table with this resource, see “Automated Services” module (download as csv, xml or #jats) #RRID #OpenScience
Celldex Therapeutics ($CLDX) reported EPS of -0.71 beating estimate of -0.73 for Q4 2024. Revenue 1.175 Million Vs 1.31 Million expected.
https://fundspec.io
Build Sophisticated AI driven valuation and momentum models on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Build Sophisticated AI driven valuation and momentum models on the FundSpec App available on the AppStore or PlayStore!
February 27, 2025 at 11:36 PM
Celldex Therapeutics ($CLDX) reported EPS of -0.71 beating estimate of -0.73 for Q4 2024. Revenue 1.175 Million Vs 1.31 Million expected.
https://fundspec.io
Build Sophisticated AI driven valuation and momentum models on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Build Sophisticated AI driven valuation and momentum models on the FundSpec App available on the AppStore or PlayStore!
B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Xencor, MEI Pharma, Celldex Thera
B-cell Non-hodgkin Lymphoma Pipeline Insights DelveInsight’s, “B-Cell Non-Hodgkin Lymphoma – Pipeline Insight, 2025”…
B-cell Non-hodgkin Lymphoma Pipeline Insights DelveInsight’s, “B-Cell Non-Hodgkin Lymphoma – Pipeline Insight, 2025”…
B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Xencor, MEI Pharma, Celldex Thera
B-cell Non-hodgkin Lymphoma Pipeline Insights DelveInsight’s, “B-Cell Non-Hodgkin Lymphoma – Pipeline Insight, 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
www.pressreleasecc.com
July 3, 2025 at 12:10 AM
B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Xencor, MEI Pharma, Celldex Thera
B-cell Non-hodgkin Lymphoma Pipeline Insights DelveInsight’s, “B-Cell Non-Hodgkin Lymphoma – Pipeline Insight, 2025”…
B-cell Non-hodgkin Lymphoma Pipeline Insights DelveInsight’s, “B-Cell Non-Hodgkin Lymphoma – Pipeline Insight, 2025”…
📢 Hampton, Nj is #hiring a Sr. Director, Epidemiology, Immunology!
🌎 Celldex Therapeutics
🔗 http://jbs.ink/LTcx4YJHduQU
#jobalert #jobsearch #familyofficejobs #marketing #design
🌎 Celldex Therapeutics
🔗 http://jbs.ink/LTcx4YJHduQU
#jobalert #jobsearch #familyofficejobs #marketing #design
August 28, 2026 at 3:57 PM
📢 Hampton, Nj is #hiring a Sr. Director, Epidemiology, Immunology!
🌎 Celldex Therapeutics
🔗 http://jbs.ink/LTcx4YJHduQU
#jobalert #jobsearch #familyofficejobs #marketing #design
🌎 Celldex Therapeutics
🔗 http://jbs.ink/LTcx4YJHduQU
#jobalert #jobsearch #familyofficejobs #marketing #design
Purcell & Lefkowitz LLP Launches Investigation into Celldex Therapeutics for Shareholder Rights#USA#New_York#Shareholder_Rights#Purcell_&_Lefkowitz#Celldex_Therapeutics
Purcell & Lefkowitz LLP Launches Investigation into Celldex Therapeutics for Shareholder Rights
Purcell & Lefkowitz LLP is probing potential breaches of fiduciary duty by Celldex Therapeutics's directors, focusing on shareholder rights. Learn more about your options.
third-news.com
August 24, 2026 at 12:57 PM
Purcell & Lefkowitz LLP Launches Investigation into Celldex Therapeutics for Shareholder Rights#USA#New_York#Shareholder_Rights#Purcell_&_Lefkowitz#Celldex_Therapeutics